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Background
Highly attenuated poxvirus strains such as MVA and
NYVAC expressing HIV components have been evaluated
as vaccines in monkeys and in human trials with encour-
aging results.
Methods
In an effort to further improve the immunogenicity of
poxvirus based vaccine candidates against HIV/AIDS, we
have developed a novel vector by inserting a VACV host-
range (hr) gene in the attenuated NYVAC-B recombinant
which expresses HIV-1 antigens from clade B (Env, Gag,
Pol and Nef). We have previously described that the pres-
ence of hr gene in NYVAC genome prevents the induction
of apoptosis and renders the vector capable of replication
in human and murine cell lines while maintaining an
attenuated phenotype in mice (Najera et al., 2006).
Results
In the present study, we have compared the in vitro anti-
gen expression after NYVAC-B or NYVAC-B-(hr) infection
using fluorescent-activated cell sorting to score Gag
expressing cells. The immunogenicity of the recombinants
in Balb/c mice after DNA-prime/Poxvirus-boost regime
was evaluated by ELISPOT and intracellular cytokine
staining assay. Both recombinants elicited robust, broad
and multifunctional antigen-specific T-cell responses tar-
geting the four immunogens included in the vectors.
However, priming with DNA-B followed a booster with
NYVAC-B-(hr) significantly enhanced the magnitude and
quality of the specific cellular immune responses in com-
parison to that elicited in animals that received DNA-B/
NYVAC-B.
Conclusion
These data demonstrate the possibility to enhance the
immunogenicity of the highly attenuated NYVAC vector
by the insertion of a host-range gene and suggest the use
of this modified vector as an improved vaccine candidate
against HIV/AIDS.
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